256 Newsroom — Uganda's Digital News Infrastructure
Health

Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T - Endpoints News

Share
Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T - Endpoints News
Image · Endpoints.news

What the report says

RiboX confirms a patient died in its unregulated China trial for RXIM002, an in vivo CAR-T therapy — the third such disclosed death in recent weeks.

Read the full report at Endpoints.news →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

Related reporting